metabolic syndrome
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The level of BMI (body mass index) is over 25.0
Exclusion criteria
Exclusion criteria: 1. Who has a serious disease under treatment. 2. Who is taking in pharmaceutical products, a supplement 3. Who participates in other clinical trials within three months before agreement acquisition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In this study, the patients of metabolic syndrome (tendency) are included. Kyo Kurenai and TCL-499 involved drink are used to intake of carotenoids. The period of intake is 8 weeks (60days) and before and after the intake, blood examination involving metaboloam-related item and special items such as s-LOX1, carotenoid, immunity, inflammation, mitochondrial function index, urinalysis, physiological function, measuring visceral fat area, and meal nourishment investigation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Using blood samples, DNS micro array is performed and based on its data, effective biomarker is screened. | — |
Countries
Japan
Contacts
Kyoto prefectural University of Medicine Molecular Gastroenterology and Hepatology